Open Government Portal
The purpose of this Notice of Amendment is to announce the revised listing for hydrocortisone on the Prescription Drug List (PDL).
The purpose of this Notice of Amendment is to notify about the addition of hydroquinone or its derivatives to the Prescription Drug List (PDL) for human use when sold in concentrations greater than 2% in topical products.
The purpose of this Notice of Intent to Amend is to notify that, as a result of consultation, Health Canada will switch certain uses of Ibuprofen to nonprescription status for human use by modifying the Human Prescription Drug List (PDL). The Veterinary List will remain unchanged.
The purpose of this Notice of Amendment is to notify that Health Canada has revised the listing for levonorgestrel on the Prescription Drug List (PDL). Only the Human part of the PDL was revised; the listing for Veterinary use will remain unchanged.
The purpose of this Notice of Amendment is to announce the revised listing for lovastatin on the Prescription Drug List (PDL). As stated in the Notice of Intent to Amend, posted June 4, 2014, the revision will allow lovastatin to be marketed as a nonprescription product. Only the Human part of the PDL has been revised.
The purpose of this Notice of Amendment is to notify that Health Canada has revised the listing for Adrenocortical hormones on the Prescription Drug List (PDL) to allow the nonprescription use of Mometasone furoate for the conditions listed below. Only the Human part of the PDL was revised.
The purpose of this Notice of Intent to Amend is to notify that, as a result of consultation, Health Canada will switch certain uses of Polymyxin B to prescription status for veterinary use by adding it to the Veterinary Prescription Drug List (PDL).
The purpose of this Notice of Amendment is to announce the revised listing for Adrenocortical hormones to allow the nonprescription use of triamcinolone acetonide for the conditions listed below. Only the Human part of the PDL has been revised.
A Notice of Compliance is a notification, issued pursuant to paragraph C.08.004(1)(a), indicating that a manufacturer has complied with sections C.08.002 or C.08.003 and C.08.005.1 of the Food and Drug Regulations. Notices of Compliance are issued to a manufacturer following the satisfactory review of a submission.
The award-winning Health Infobase, a sub-domain of Canada.ca, provides Canadian health information on a wide variety of topics including chronic and infectious diseases, injuries, mental health, health behaviours, health inequalities, consumer products, pesticides, wastewater, wildfires, and many more.
In collaboration with subject matter experts, the Health Infobase team develops easy-to-use data visualizations including interactive and accessible data tools, allowing users to easily access, explore and understand Canadian health information.
By using both filters and free-text search options, users can view data products from different data sources in both static and interactive formats. Many data products have downloadable data sets, which …